You are currently viewing Lupin Partners with Mark Cuban’s Company and COPD Foundation for Affordable Lung Medications

Lupin Partners with Mark Cuban’s Company and COPD Foundation for Affordable Lung Medications

Lupin Ltd, a pharmaceutical company, has partnered with Mark Cuban’s Cost Plus Drugs and the COPD Foundation to improve the availability and affordability of drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in the United States. Here are the key details of this partnership:

COPD Treatment: COPD is a severe and life-threatening respiratory condition that affects more than 15 million adults in the United States and is the fourth leading cause of death in the country.

Lupin’s Contribution: Lupin will contribute its Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, which is a generic product equivalent to Spiriva HandiHaler by Boehringer Ingelheim Pharmaceuticals, Inc. This medication is used for the treatment of COPD.

Unmet Need: Lupin’s President of US Generics, Spiro Gavaris, highlighted the significant unmet need for improved and affordable products for patients in the United States. The partnership aims to address this need by providing treatment options for respiratory conditions like COPD, leveraging Lupin’s respiratory portfolio and pipeline.

Cost Plus Drugs: Alex Oshmyansky, CEO of Cost Plus Drugs, emphasized that consumers can expect fair pricing and the convenience of having medications delivered directly to their homes through Cost Plus Drugs.

Stock Performance: Following this announcement, shares of Lupin Ltd ended positively on the Bombay Stock Exchange (BSE), reflecting the positive sentiment around this partnership and its potential impact on the company’s business.

This collaboration underscores the importance of improving access to essential medications for patients suffering from COPD in the United States. By joining forces with Cost Plus Drugs and the COPD Foundation, Lupin aims to make a meaningful contribution to addressing the healthcare needs of COPD patients and increasing the affordability and availability of vital treatments for this condition.